Literature DB >> 22416109

Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas.

Johan Pallud1, Jean-François Llitjos, Frédéric Dhermain, Pascale Varlet, Edouard Dezamis, Bertrand Devaux, Raphaëlle Souillard-Scémama, Nader Sanai, Maria Koziak, Philippe Page, Michel Schlienger, Catherine Daumas-Duport, Jean-François Meder, Catherine Oppenheim, François-Xavier Roux.   

Abstract

Quantitative imaging assessment of radiation therapy (RT) for diffuse low-grade gliomas (DLGG) by measuring the velocity of diametric expansion (VDE) over time has never been studied. We assessed the VDE changes following RT and determined whether this parameter can serve as a prognostic factor. We reviewed a consecutive series of 33 adults with supratentorial DLGG treated with first-line RT with available imaging follow-up (median follow-up, 103 months). Before RT, all patients presented with a spontaneous tumor volume increase (positive VDE, mean 5.9 mm/year). After RT, all patients demonstrated a tumor volume decrease (negative VDE, mean, -16.7 mm/year) during a mean 49-month duration. In univariate analysis, initial tumor volume (>100 cm(3)), lack of IDH1 expression, p53 expression, high proliferation index, and fast post-RT tumor volume decrease (VDE at -10 mm/year or faster, fast responders) were associated with a significantly shorter overall survival (OS). The median OS was significantly longer (120.8 months) for slow responders (post-RT VDE slower than -10.0 mm/year) than for fast responders (47.9 months). In multivariate analysis, fast responders, larger initial tumor volume, lack of IDH1 expression, and p53 expression were independent poor prognostic factors for OS. A high proliferation index was significantly more frequent in the fast responder subgroup than in the slow responder subgroup. We conclude that the pattern of post-RT VDE changes is an independent prognostic factor for DLGG and offers a quantitative parameter to predict long-term outcomes. We propose to monitor individually the post-RT VDE changes using MRI follow-up, with particular attention to fast responders.

Entities:  

Mesh:

Year:  2012        PMID: 22416109      PMCID: PMC3309865          DOI: 10.1093/neuonc/nos069

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  27 in total

Review 1.  [Gliomas: WHO and Sainte-Anne Hospital classifications].

Authors:  C Daumas-Duport; F Beuvon; P Varlet; C Fallet-Bianco
Journal:  Ann Pathol       Date:  2000-10       Impact factor: 0.407

2.  Low-grade gliomas in children: tumor volume response to radiation.

Authors:  B J Fisher; G S Bauman; C E Leighton; L Stitt; J G Cairncross; D R Macdonald
Journal:  J Neurosurg       Date:  1998-06       Impact factor: 5.115

3.  Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria.

Authors:  C Daumas-Duport; M L Tucker; H Kolles; P Cervera; F Beuvon; P Varlet; N Udo; M Koziak; J P Chodkiewicz
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

4.  Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases.

Authors:  C Daumas-Duport; P Varlet; M L Tucker; F Beuvon; P Cervera; J P Chodkiewicz
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

5.  Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study.

Authors:  E Shaw; R Arusell; B Scheithauer; J O'Fallon; B O'Neill; R Dinapoli; D Nelson; J Earle; C Jones; T Cascino; D Nichols; R Ivnik; R Hellman; W Curran; R Abrams
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

6.  Continuous growth of mean tumor diameter in a subset of grade II gliomas.

Authors:  Emmanuel Mandonnet; Jean-Yves Delattre; Marie-Laure Tanguy; Kristin R Swanson; Antoine F Carpentier; Hugues Duffau; Philippe Cornu; Rémy Van Effenterre; Ellsworth C Alvord; Laurent Capelle
Journal:  Ann Neurol       Date:  2003-04       Impact factor: 10.422

7.  Prognostic factors for survival in adult patients with cerebral low-grade glioma.

Authors:  Francesco Pignatti; Martin van den Bent; Desmond Curran; Channa Debruyne; Richard Sylvester; Patrick Therasse; Denes Afra; Philippe Cornu; Michel Bolla; Charles Vecht; Abul B M F Karim
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

Review 8.  Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.

Authors:  M J van den Bent; J S Wefel; D Schiff; M J B Taphoorn; K Jaeckle; L Junck; T Armstrong; A Choucair; A D Waldman; T Gorlia; M Chamberlain; B G Baumert; M A Vogelbaum; D R Macdonald; D A Reardon; P Y Wen; S M Chang; A H Jacobs
Journal:  Lancet Oncol       Date:  2011-04-05       Impact factor: 41.316

9.  A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844.

Authors:  A B Karim; B Maat; R Hatlevoll; J Menten; E H Rutten; D G Thomas; F Mascarenhas; J C Horiot; L M Parvinen; M van Reijn; J J Jager; M G Fabrini; A M van Alphen; H P Hamers; L Gaspar; E Noordman; M Pierart; M van Glabbeke
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-10-01       Impact factor: 7.038

Review 10.  Supratentorial grade II astrocytoma: biological features and clinical course.

Authors:  Peter H Wessels; Wim E J Weber; Guy Raven; Frans C S Ramaekers; Anton H N Hopman; Albert Twijnstra
Journal:  Lancet Neurol       Date:  2003-07       Impact factor: 44.182

View more
  27 in total

1.  Neuro-oncology: Imaging measurements can predict outcome for glioma after radiotherapy.

Authors:  Iley Ozerlat
Journal:  Nat Rev Neurol       Date:  2012-04-17       Impact factor: 42.937

2.  Impact of imaging measurements on response assessment in glioblastoma clinical trials.

Authors:  David A Reardon; Karla V Ballman; Jan C Buckner; Susan M Chang; Benjamin M Ellingson
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

3.  Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas.

Authors:  Johan Pallud; Marie Blonski; Emmanuel Mandonnet; Etienne Audureau; Denys Fontaine; Nader Sanai; Luc Bauchet; Philippe Peruzzi; Marc Frénay; Philippe Colin; Rémy Guillevin; Valérie Bernier; Marie-Hélène Baron; Jacques Guyotat; Hugues Duffau; Luc Taillandier; Laurent Capelle
Journal:  Neuro Oncol       Date:  2013-02-07       Impact factor: 12.300

Review 4.  'Low grade glioma': an update for radiologists.

Authors:  Jennifer Larsen; Steve B Wharton; Fiona McKevitt; Charles Romanowski; Caroline Bridgewater; Hesham Zaki; Nigel Hoggard
Journal:  Br J Radiol       Date:  2016-12-07       Impact factor: 3.039

5.  Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.

Authors:  Catherine Gozé; Marie Blonski; Guillaume Le Maistre; Luc Bauchet; Edouard Dezamis; Philippe Page; Pascale Varlet; Laurent Capelle; Bertrand Devaux; Luc Taillandier; Hugues Duffau; Johan Pallud
Journal:  Neuro Oncol       Date:  2014-05-20       Impact factor: 12.300

6.  Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma.

Authors:  Jasmin Jo; Brian Williams; Mark Smolkin; Max Wintermark; Mark E Shaffrey; M Beatriz Lopes; David Schiff
Journal:  J Neurooncol       Date:  2014-07-20       Impact factor: 4.130

7.  Is the volume of low-grade glioma measurable and is it clinically relevant?

Authors:  Marc C Chamberlain
Journal:  Neuro Oncol       Date:  2014-06-20       Impact factor: 12.300

8.  Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.

Authors:  C Izquierdo; A Alentorn; A Idbaih; M Simó; G Kaloshi; D Ricard; M Barritault; D Meyronet; J Bruna; J Honnorat; J Y Delattre; F Ducray
Journal:  J Neurooncol       Date:  2017-11-15       Impact factor: 4.130

9.  Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.

Authors:  Walter Taal; Carin C D van der Rijt; Winand N M Dinjens; Peter A E Sillevis Smitt; Agnes A A C M Wertenbroek; Jacoline E C Bromberg; Irene van Heuvel; Johan M Kros; Martin J van den Bent
Journal:  J Neurooncol       Date:  2014-10-26       Impact factor: 4.130

10.  Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients.

Authors:  Marie Blonski; Johan Pallud; Catherine Gozé; Emmanuel Mandonnet; Valérie Rigau; Luc Bauchet; Michel Fabbro; Patrick Beauchesne; Marie-Hélène Baron; Denys Fontaine; Philippe Peruzzi; Amélie Darlix; Hugues Duffau; Luc Taillandier
Journal:  J Neurooncol       Date:  2013-03-12       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.